Posted by Michael Wonder on 27 Jan 2026
MannKind announces FDA approval of updated Afrezza label providing starting dose guidance when switching from multiple daily injections or insulin pump mealtime therapy
26 January 2026 - Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic excursions.
MannKind Corporation today announced that the US FDA has approved an update to the Prescribing Information for Afrezza (insulin human) inhalation powder, revising recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens.
